A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 300 participants.

Also called NCT06305559

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06305559
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06305559. Randomized; quadruple masking; primary purpose prevention. Start 2024-05-16 (actual); primary completion 2027-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
Acronym
REMBRANDT
Condition
Lipidemia
Condition
Plaque, Atherosclerotic
Intervention (Drug)
obicetrapib 10 mg + ezetimibe 10 mg FDC daily
Intervention (Other)
Placebo
Lead sponsor
NewAmsterdam Pharma (class: industry)

Record details

Record id
cardio:ct-nct06305559
Content hash
6435eca96d3ab6d635836dd7bfb6fa684cd31577fc12491177404ca0e0d11bde